Outcomes | Anticipated absolute effects (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments | |
---|---|---|---|---|---|---|
Risk with placebo | Risk with galcanezumab | |||||
Reduction in migraine days follow up: 6 months | The mean reduction in migraine days was −2.8 days | The mean reduction in migraine days in the intervention group was 1.9 days fewer (2.5 fewer to 1.4 fewer) | – | 646 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 120 mg results in reduction in migraine days compared with placebo. |
Reduction in use of acute attack medication follow up: 6 months | The mean reduction in use of acute attack medication was −2.2 days | The mean reduction in use of acute attack medication in the intervention group was 1.8 days fewer (2.3 fewer to 1.3 fewer) | – | 646 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 120 mg results in reduction in use of acute attack medication compared with placebo. |
Improvement in functional MSQ RFR score follow up: 6 months | The mean improvement in functional MSQ RFR score was 24.7 points | The mean improvement in functional MSQ RFR score in the intervention group was 7.7 points higher (5.2 higher to 10.3 higher) | – | 646 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 120 mg results in improvement in functional MSQ RFR score compared with placebo. |
At least 50% reduction in days of migraine follow up: 6 months | 386 per 1000 | 623 per 1000 (533 to 731) | RR 1.6190 (1.3823 to 1.8962) | 646 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 120 mg results in at least 50% reduction of days of migraine compared with placebo. |
Serious adverse events follow up: 12–6 months | 12 per 1000 | 28 per 1000 (9 to 91) | RR 2.4394 (0.7530 to 7.9028) | 646 (1 RCTs) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 120 mg results a small possibly unimportant effect in serious adverse events occurrence compared with placebo |
Mortality follow up: 3–6 months | 0 per 1000 | 0 per 1000 (0 to 0) | not estimable | 646 (1 RCTs) | No deaths occurred during the double-blind treatment phase of the trial. |